Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- blood sample will be done for dosage of Fractalkine in the serum
研究概览
简要总结
Systemic Sclerosis (SSc) is an auto-immune systemic disease characterized by vascular damage, cutaneous and visceral fibrosis and a dysimmune condition.
Therapies in this disease remain insufficient and the complications resulting from organs involvement lead to strong morbi-mortality.The dermic infiltrate of the patients includes a strong proportion of Tcells. T cells and Natural Killer (NK) cells are potentially involved in the vascular damage of the SSc. However mechanisms at the onset of this endothelial cytotoxicity and its impact on the capacities of regeneration of the endothelial tissue remain poorly understood. Fractalkine is at the same time an endothelial membrane-bound adhesion molecule and a chemokine which is able to bind CX3CR1 expressed by the immune populations. The purpose of the project is to define the role displayed by cytotoxic, circulating immune populations of SSc patients in endothelial cytotoxicity as well as the role of the axis Fractalkine / CX3CR1 in mediating the interactions between the immune cytotoxic cells and the endothelium.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •patients affected by SSc of more than 18 years
- •Healthy patients
排除标准
- •Impossibility to take some blood
- •Current infection
- •Ongoing cancer
- •chemotherapy or a current radiotherapy
- •pregnant or breast-feeding women
研究组 & 干预措施
Systemic Sclerosis (SSc) patient
15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
干预措施: blood samples (Other)
healthy patient
15 healthy patients will be recruited and blood samples will be obtained
干预措施: blood samples (Other)
结局指标
主要结局
blood sample will be done for dosage of Fractalkine in the serum
时间窗: 12 months
次要结局
- blood sample for functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC)(12 months)
